35053-55-5

Upstream product

• 5469-69-2 6-chloro-pyridazin-3-ylamine 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 

Downstream Products

• 90734-72-8 (6-chloroimidazo[1,2-b]pyridazin-3-yl)(phenyl)methanone 
• 90734-71-7 1-{6-chloroimidazo[1,2-b]pyridazin-3-yl}ethan-1-one 
• 51519-15-4 3-(hydroxyiminomethyleneamino)-6-chloropyridazine 
• 124211-86-5 2-phenyl-4-(6-chloro-3-pyridazinylamino)methylene-5(4H)oxazolone 
• 42399-79-1 6-Chloro[1,2,4]triazolo[1,5-b]pyridazine 
• 152537-78-5 6-(3-sulfamoyl-1-propoxy)[1,2,4]triazolo[1,5-b]pyridazine 
• 152537-14-9 6-(2,2-dimethyl-3-sulfamoyl-1-propoxy)[1,2,4]triazolo[1,5-b]pyridazine 
• 152537-56-9 6-(2,2-diethyl-3-sulfamoyl-1-propoxy)[1,2,4]triazolo[1,5-b]pyridazine 
• 83412-75-3 6-Chloro-3-cyanoaminopyridazine 
• 123531-54-4 6-chloroimidazo[1,2-b]pyridazine-3-carbonitrile 
• 1150566-27-0 6-chloroimidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester 
• 1365212-67-4 6-[(2R,4S)-4-fluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide 
• 1365213-30-4 N-(3-cyanophenyl)-6-[(2R)-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide 
• 1365213-74-6 6-[(2R,4S)-4-fluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]-N-(2-fluoroethyl)imidazo[1,2-b]pyridazine-3-carboxamide 

Relevant academic research and scientific papers

Synthesis method of 6-chloroimidazo[1, 2-b]pyridazine-3-carbonitrile

The invention relates to a synthesis method of 6-chloroimidazo[1, 2b]pyridazine-3-carbonitrile, which comprises the following steps of 1, adding N, N-dimethylformamide dimethyl acetal into a reactor to react with 3-amino-6-chloropyridazine, thereby obtaining an N, N-dimethyl-N'-3-(6-chloro-pyridazine)yl-formamidine intermediate; 2, adding a solvent into the N, N-dimethyl-N'-3-(6-chloro-pyridazine)yl-formamidine intermediate obtained in the step 1, mixing, adding bromoacetonitrile, reacting, adding alkali liquor, standing, separating out solid, and filtering to obtain a solid mixture, 3, completely dissolving the solid mixture obtained in the step 4 in ethyl acetate, washing with water and saturated edible salt water, drying, filtering, and removing ethyl acetate to obtain a crude product of 6-chloroimidazo[1, 2-b]pyridazine-3-carbonitrile, and 4, recrystallizing the crude product of the 6-chloroimidazo[1, 2-b]pyridazine-3-carbonitrile, and filtering to obtain a pure product of the 6-chloroimidazo[1, 2-b] pyridazine-3-carbonitrile. The method is short in overall process time, and the obtained product is stable in quality and high in purity.

HERBICIDAL COMPOUNDS

Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

Synthetic method of 6-chloroimidazo [1, 2-b]pyridazine-3-formic acid

The invention relates to a synthetic method of 6-chloroimidazo [1, 2-b]pyridazine-3-formic acid. The synthetic method comprises the steps of reacting N,N-dimethylformamide dimethyl acetal and 3-amino-6-chloropyridazine at the temperature of 40 to 120 DEG C to obtain an intermediate; under an alkali action, reacting at the temperature of 65 to 140 DEG C, and carrying out rotary evaporation and concentration to obtain a 6-chloroimidazo [1,2-b]pyridazine-3-formic acid ethyl ester crude product; recrystallizing the crude product to obtain a pure product; under an alkali action, carrying out hydrolysis reaction in a certain solvent, finishing reaction, neutralizing through hydrochloric acid, carrying out suction filtration, and washing drying to obtain a 6-chloroimidazo [1, 2-b]pyridazine-3-formic acid pure product. The synthetic method provided by the invention is adopted for preparing the 6-chloroimidazo [1, 2-b]pyridazine-3-formic acid, so that the reaction raw materials can be obtained easily, the method is easy to operate and control and simple in aftertreatment, and the product has stable quality and high purity.

TGF-Beta Inhibitors

Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R′ are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-β, and can be used to treat disease by blocking TGF-β signaling.

COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.

HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

HETEROCYCLIC OXIME COMPOUNDS

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

New adenosine receptor ligands and uses thereof

The present invention provides new compounds with high affinity for adenosine A2A receptors. It also provides antagonists of adenosine A2A receptors and their use as medicaments for the treatment and/or prophylaxis of diseases and di

IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE

The invention relates to compounds of formula (I) and salts thereof, formula (I) wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharamaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).

Synthetic studies on condensed-azole derivatives. V. Synthesis and anti- asthmatic activities of ω-sulfamoylalkyloxy[1,2,4]triazolo[1,s-b]pyridazines

A series of novel ([1,2,4]triazolo[1,5-b]pyridazin-6- yl)oxyalkylsulfonamides was synthesized and evaluated for the ability to inhibit platelet activating factor (PAF)-induced bronchoconstriction in guinea pigs. The compounds bearing a gem-dialkyl or a cycloalkylidene group at the 2 position of the sulfamoylpropyloxy group in the side chain and a methyl group at the 7 position were found to have potent activity. Among them, 2,2-diethyl-3-(7-methyl[l,2,4]-triazolo[1,5-b]pyridazin-6- yl)oxypropanesulfonamide (13) showed excellent anti-asthmatic activity. Compouds 13 may be of significant value in the treatment of asthma and other respiratory diseases. The structure-activity relationships in this series of compounds are discussed.